FogPharma® Secures $145 Million in Series E Funding to Revolutionize Cancer Treatment with Pioneering Helicon™ Peptide Technology

FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently availabl...

March 04, 2024 | Monday | News
Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States

The test is covered by Medicare and many commercial insurance plans for eligible patients   Exact Sciences Corp., a leading provider of cancer scree...

February 29, 2024 | Thursday | News
FDA-approved generic provides cost-effective option for treating cancer

Fresenius Kabi announced  it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms o...

February 29, 2024 | Thursday | News
Curve Therapeutics Secures £40.5 Million Series A Funding Led by Pfizer Ventures to Propel Cancer Drug Discovery Efforts

Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined ...

February 28, 2024 | Wednesday | News
Aleta Biotherapeutics and Cancer Research UK Launch ALETA-001 Phase 1/2 Trial for Relapsed B-Cell Malignancies

Aleta Biotherapeutics (Aleta), a pioneer in immuno-oncology with a focus on CAR T-Cell Engager (CTE) platforms, in collaboration with Cancer Research UK&rs...

February 21, 2024 | Wednesday | News
Ultimovacs' UV1 Cancer Vaccine Granted EMA Orphan Drug Designation for Mesothelioma Treatment

Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines,  announced tha...

February 19, 2024 | Monday | News
Vidac Pharma's VDA-1275 Shows Promising Efficacy Across Solid Tumor Models and Enhances Standard Treatments

Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed prom...

February 19, 2024 | Monday | News
Daiichi Sankyo and AstraZeneca's Datopotamab Deruxtecan BLA Accepted in U.S. for Advanced Nonsquamous NSCLC Treatment

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have announced the acceptance of their Biologics License Application (BLA) for datopotamab...

February 19, 2024 | Monday | News
iNtRON Biotechnology Advances Cancer Treatment with PHAGERIA®, Harnessing Robot Bacteriophage Platform

  iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has unveiled a groundbreaking development in cancer treatment with the announcement of PHAGERI...

February 15, 2024 | Thursday | News
Curasight Announces Accelerated Basket Trial Targeting Five Cancer Indications

Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) is forging ahead with its mission to revolutionize cancer treatment, announcing today the acceler...

February 13, 2024 | Tuesday | News
Pfizer's Epic Quest: Unleashing a Symphony of Science Against Cancer!

Pfizer's innovative campaign merges iconic science with a legendary song, captivating millions in the fight against cancer. Rooted in a 175-year legacy of ...

February 12, 2024 | Monday | News
Auron Therapeutics Unveils Groundbreaking Cancer Treatment Candidate AUTX-703 from AURIGIN™ Platform

    Auron Therapeutics, a pioneering biotechnology firm dedicated to advancing targeted cancer therapies, has announced the selection of its in...

February 08, 2024 | Thursday | News
Novartis Bolsters Oncology Portfolio with MorphoSys AG Acquisition for EUR 2.7 Billion

The acquisition encompasses key assets such as pelabresib, a promising late-stage BET inhibitor for myelofibrosis (MF), and tulmimetostat, an early-stage i...

February 06, 2024 | Tuesday | News
Qubit Pharma, Institut Curie, and University of Bordeaux Collaborate on Innovative Cancer Therapies

The three partners are joining forces to develop drug candidates that modulate the immune response of cancer patients and block the development of metast...

January 30, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close